Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-scale discovery platform enables identification of peptides targeting drug-resistant candidiasis.

Cell reports methods·2026
Same author

Are CD4<sup>+</sup> T-Cell Counts Associated with <i>Pneumocystis jirovecii</i> Detection in Hospitalized Patients with Liver Disease? A Retrospective Exploratory Pilot Analysis.

Livers·2026
Same author

The iron-responsive transcription factor HapX drives iron starvation adaptation and virulence in <i>Talaromyces marneffei</i>.

Current research in microbial sciences·2026
Same author

Diagnostic performance of a biotin-labeled 4D1 sandwich ELISA for serum antigen detection in talaromycosis.

PLoS neglected tropical diseases·2026
Same author

Micafungin microevolution in <i>Candida auris</i> reveals resistance development without <i>in vivo</i> fitness compromise.

Virulence·2026
Same author

Protein-related hydrophobicity differences among strains belonging to <i>Candidozyma auris</i> (<i>Candida auris</i>) clades.

Microbiology spectrum·2026

Related Experiment Video

Updated: May 24, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Antibody therapy for histoplasmosis.

Joshua D Nosanchuk1, Rosely M Zancopé-Oliveira, Andrew J Hamilton

  • 1Department of Medicine, Albert Einstein College of Medicine Bronx, NY, USA.

Frontiers in Microbiology
|February 21, 2012
PubMed
Summary

New antibody therapies show promise in treating histoplasmosis, a serious fungal infection caused by Histoplasma capsulatum. Monoclonal antibodies targeting fungal or host molecules offer potential new strategies for managing this disease.

Keywords:
Histoplasma capsulatumM antigenantibodyco-stimulationheat shock protein 60histone 2Bhistoplasmosis

More Related Videos

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

Related Experiment Videos

Last Updated: May 24, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

Area of Science:

  • Mycology
  • Immunology
  • Infectious Diseases

Background:

  • Histoplasma capsulatum is an endemic fungus causing diverse clinical presentations of histoplasmosis, from mild to life-threatening systemic infections.
  • Current treatments like azoles and amphotericin B are effective but mortality remains significant, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To review the current understanding of antibody therapy's impact on histoplasmosis pathogenesis.
  • To explore the potential of monoclonal antibodies (mAbs) as a novel treatment strategy.

Main Methods:

  • Review of scientific literature on antibody therapy for histoplasmosis over the past 10 years.
  • Analysis of studies investigating mAbs targeting fungal cell surface proteins and host co-stimulatory molecules.

Main Results:

  • Monoclonal antibodies have demonstrated the ability to modulate the pathogenesis of histoplasmosis.
  • Targeting either fungal or host molecules with mAbs can impact disease progression.

Conclusions:

  • Antibody-based therapies represent a promising avenue for managing histoplasmosis.
  • Further research into mAb mechanisms and clinical efficacy is warranted for this significant fungal pathogen.